Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | China In-Depth | China

Among the four subtypes of non-Hodgkin’s lymphoma (NHL), diffuse large B-cell lymphoma DLBCL is the most common in China. Rituximab (Roche’s MabThera, biosimilars) continues to dominate China’s NHL market owing to a favorable and well-established clinical profile, particularly as part of the R-CHOP chemotherapy regimen. However, rituximab’s market dominance is likely to be challenged by novel, emerging targeted therapies that we expect will launch in a few years. The launch of these therapies will allow the Chinese non-Hodgkin’s lymphoma (NHL) market to grow significantly during the forecast period, despite the launch of cost-effective biosimilars and generics of rituximab and lenalidomide, respectively, starting in 2019. The high unmet need for effective targeted therapies for NHL in China presents a commercial opportunity for developers. Additionally, the ongoing reforms in the regulatory and access and reimbursement landscape of China will encourage multinational corporations (MNCs) to enter the market.

  1. How large is China’s drug-treatable non-Hodgkin’s lymphoma population, and how will the drug-treatment rate change during the forecast period?
  2. What are the most commercially relevant drugs in China’s non-Hodgkin’s lymphoma market, and why? What are interviewed experts’ insights into current treatment options? Which clinical needs remain unfulfilled?
  3. What are the major market access considerations for key therapies in the non-Hodgkin’s lymphoma pipeline in China? What sales/uptake could they secure in non-Hodgkin’s lymphoma?
  4. What are the key drivers and constraints in the Chinese non-Hodgkin’s lymphoma market, and how will the market evolve over the forecast period?


China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.


July 2020




Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and 75 surveys with hematologist-oncologists. Supported by survey data collected for this and other DRG research.


Diagnosed incidence of non-Hodgkin’s lymphoma in urban versus rural China; clinically relevant and market-relevant drug-treatable populations


10-year, annualized, drug-level sales and patient shares of key non-Hodgkin’s lymphoma regimens through 2029, based on primary and secondary market research to formulate bottom-up assumptions


Phase III/PR: 5+ drugs; Phase II: 10+ drugs; coverage of select preclinical and Phase I products

Login to access report

launch Related Market Assessment Reports